Clinical Trial Update: Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating alemtuzumab in patients with B-cell chronic lymphocytic leukemia who are in partial or complete remission. The study has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• CAMPATH (ALEMTUZUMAB)

Snippet

Sponsor: Leeds Cancer Centre at St. James's University Hospital | Conditions: Leukemia | Phase 2 | Status: COMPLETED